Higher FAP levels were found to correlate with poorer response and clinical outcomes in bladder urothelial carcinoma and cutaneous melanoma patients undergoing treatment with immune checkpoint inhibitors (56). This evidence concerns the gene FAP and cutaneous melanoma.